{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:27:09Z","timestamp":1791487629564,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":793,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4704-B20"],"award-info":[{"award-number":["F4704-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1093\/annonc\/mdx290","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T19:09:51Z","timestamp":1496776191000},"page":"2367-2376","source":"Crossref","is-referenced-by-count":74,"title":["Midostaurin: a magic bullet that blocks mast cell expansion and activation"],"prefix":"10.1016","volume":"28","author":[{"given":"P.","family":"Valent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.V.","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.W.","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-P.","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx290_bb0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2559.1979.tb03017.x","article-title":"Mast cells and mast cell neoplasia: a review","volume":"3","author":"Lennert","year":"1979","journal-title":"Histopathology"},{"issue":"3S","key":"10.1093\/annonc\/mdx290_bb0015","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1111\/1523-1747.ep12469022","article-title":"The liver, spleen, and lymph nodes in mastocytosis","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1093\/annonc\/mdx290_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"Horny","year":"2001","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdx290_bb0025","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1111\/1523-1747.ep12468882","article-title":"Classification and diagnosis of mastocytosis: current status","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1093\/annonc\/mdx290_bb0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx290_bb0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1093\/annonc\/mdx290_bb0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1093\/annonc\/mdx290_bb0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdx290_bb0050","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdx290_bb0055","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1093\/annonc\/mdx290_bb0060","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdx290_bb0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"10.1093\/annonc\/mdx290_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx290_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms","volume":"114","author":"Valent","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1093\/annonc\/mdx290_bb0080","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0085","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0090","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0025-6196(12)62636-6","article-title":"Mast cell leukemia: report of a case and review of the literature","volume":"61","author":"Travis","year":"1986","journal-title":"Mayo Clin Proc"},{"key":"10.1093\/annonc\/mdx290_bb0095","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0100","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdx290_bb0105","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0110","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx290_bb0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3324\/haematol.12324","article-title":"How we diagnose and treat WHO-defined systemic mastocytosis in adults","volume":"93","author":"Tefferi","year":"2008","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx290_bb0120","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0125","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1111\/j.0960-135X.2004.01369.x","article-title":"On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts","volume":"34","author":"Valent","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1093\/annonc\/mdx290_bb0130","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0140","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx290_bb0145","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdx290_bb0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdx290_bb0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","article-title":"Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis","volume":"113","author":"Fritsche-Polanz","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx290_bb0160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000048179","article-title":"Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts","volume":"127","author":"F\u00e9ger","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1093\/annonc\/mdx290_bb0165","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdx290_bb0170","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdx290_bb0175","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1093\/annonc\/mdx290_bb0180","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0185","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdx290_bb0190","first-page":"17","article-title":"PKC412 \u2013 a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro","year":"2000","journal-title":"Anticancer Drug Des"},{"key":"10.1093\/annonc\/mdx290_bb0195","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1093\/annonc\/mdx290_bb0200","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx290_bb0205","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1515403","article-title":"Midostaurin in advanced systemic mastocytosis","volume":"374","author":"Chandesris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx290_bb0210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0006-291X(86)90008-2","article-title":"Staurosporine, a potent inhibitor of phospholipid\/Ca\u2009++dependent protein kinase","volume":"135","author":"Tamaoki","year":"1986","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdx290_bb0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1093\/annonc\/mdx290_bb0220","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdx290_bb0225","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR\u03b1-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdx290_bb0230","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1053\/j.gastro.2006.09.017","article-title":"Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity","volume":"131","author":"Weisberg","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdx290_bb0235","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/0008-5472.CAN-08-2923","article-title":"FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro","volume":"69","author":"von Bubnoff","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx290_bb0240","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0065-2776(01)76022-1","article-title":"Signal transduction by the high-affinity immunoglobulin E receptor Fc epsilon RI: coupling form to function","volume":"76","author":"Nadler","year":"2000","journal-title":"Adv Immunol"},{"key":"10.1093\/annonc\/mdx290_bb0245","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0161-5890(02)00068-8","article-title":"Protein tyrosine kinase Syk in mast cell signaling","volume":"38","author":"Siraganian","year":"2002","journal-title":"Mol Immunol"},{"key":"10.1093\/annonc\/mdx290_bb0250","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","article-title":"Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C","volume":"19","author":"Propper","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx290_bb0255","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors","volume":"108","author":"Levis","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0260","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0091270008318006","article-title":"Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus","volume":"48","author":"Wang","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdx290_bb0265","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","article-title":"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers","volume":"72","author":"Dutreix","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdx290_bb0270","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","article-title":"A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection","volume":"124","author":"Saleh","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0275","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","article-title":"Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs","volume":"114","author":"Aichberger","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0280","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","article-title":"Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V","volume":"98","author":"Gleixner","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx290_bb0285","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/leu.2015.138","article-title":"Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia","volume":"29","author":"Wedeh","year":"2015","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdx290_bb0290","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1189\/jlb.1112609","article-title":"The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells","volume":"95","author":"Peter","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1093\/annonc\/mdx290_bb0295","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","article-title":"KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib","volume":"118","author":"Gleixner","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0300","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2007-08-104372","article-title":"The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils","volume":"111","author":"Kneidinger","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0305","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood.V122.21.106.106","article-title":"Durable responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): updated stage 1 results of the global D2201 trial","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0310","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0315","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood.V116.21.316.316","article-title":"KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial","volume":"116","author":"Gotlib","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0320","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.18632\/oncotarget.3074","article-title":"Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia","volume":"6","author":"Cerny-Reiterer","year":"2015","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdx290_bb0325","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood.V84.9.2954.2954","article-title":"Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation","volume":"84","author":"F\u00f6dinger","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0330","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2005-06-2469","article-title":"Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain","volume":"107","author":"Heidel","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0335","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdx290_bb0340","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdx290_bb0345","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx290_bb0350","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0355","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jaci.2015.07.006","article-title":"Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity","volume":"137","author":"Rabenhorst","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1093\/annonc\/mdx290_bb0360","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V124.21.817.817","article-title":"Identification of a neoplastic stem cell in human mast cell leukemia","volume":"124","author":"Eisenwort","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0365","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.iac.2006.05.003","article-title":"KIT mutations in mastocytosis and their potential as therapeutic targets","volume":"26","author":"Gotlib","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1093\/annonc\/mdx290_bb0370","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdx290_bb0375","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V126.23.6.6","volume":"126","author":"Stone","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx290_bb0380","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.exphem.2006.09.008","article-title":"Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils","volume":"35","author":"Krauth","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1093\/annonc\/mdx290_bb0385","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1096\/fj.14-250894","article-title":"CD52 is a molecular target in advanced systemic mastocytosis","volume":"28","author":"Hoermann","year":"2014","journal-title":"FASEB J"},{"key":"10.1093\/annonc\/mdx290_bb0390","article-title":"Midostaurin (PKC412) in indolent systemic mastocytosis: a phase 2 trial","author":"Van Anrooij","year":"2016","journal-title":"EHA Learning Center"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419349270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419349270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/10\/2367\/20232518\/mdx290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:08:13Z","timestamp":1624694893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419349270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0923753419349270"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx290","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}